U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06798909) titled 'Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients' on Jan. 17.
Brief Summary: This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily [both dose adjusted per Food and Drug Administr...